Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (NCT04229979)
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
🩺 Plain-English Summary (8th-Grade Level)
To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second or later complete remission (CR2) or second or later complete remission with incomplete platelet recovery (CRp2).
Who can join: Review the eligibility criteria below.
Location: O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- O'Neal Comprehensive Cancer Center — Birmingham, Alabama
- UCLA Medical Hematology and Oncology — Los Angeles, California
- The Oncology Institute of Hope and Innovation — Whittier, California
- Colorado Blood Cancer Institute - SCRI - PPDS — Denver, Colorado
- Mayo Clinic Jacksonville Florida — Jacksonville, Florida
- Augusta University — Augusta, Georgia
- Rush University Cancer Center — Chicago, Illinois
- Tulane Cancer Center - Liberty — New Orleans, Louisiana
- Northwell Health Cancer Institute — Lake Success, New York
- New York Medical College — Valhalla, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Oregon Health and Science University — Portland, Oregon
- Bon Secours St. Francis Cancer Center — Greenville, South Carolina
- Baylor Scott and White Research Institute — Dallas, Texas
- University of Texas - MD Anderson Cancer Center — Houston, Texas
- Virginia Cancer Specialists — Gainesville, Virginia
- Swedish Cancer Institute — Seattle, Washington
- CHU Amiens-Picardie - Hopital Sud — Amiens,
- CHU Angers — Angers,
- CHU de Caen — Caen,
- CHU de Grenoble — Grenoble,
- Hôtel Dieu - Nantes — Nantes,
- Hôpital Saint Antoine — Paris,
- Centre Hospitalier Lyon Sud — Pierre-Bénite,
- CHU de Poitiers — Poitiers,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California
Explore by condition: All Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.